2023
Mechanisms of liver fibrosis in metabolic syndrome
Mehal W. Mechanisms of liver fibrosis in metabolic syndrome. EGastroenterology 2023, 1: e100015. PMID: 37946713, PMCID: PMC10634657, DOI: 10.1136/egastro-2023-100015.Peer-Reviewed Original ResearchNon-alcoholic steatohepatitisLiver fibrosisMetabolic syndromeHepatic stellate cellsHepatocellular injuryImmune systemHSC transdifferentiationGrowth factorChronic hepatocellular injuryInnate immune cellsMetabolite changesInnate immune systemAdaptive immune systemNASH fibrosisHepatocellular damageAntifibrotic strategiesImmune cellsProfibrotic roleT cellsFree fatty acidsStellate cellsViral infectionFibrosisSyndromeEndothelial cells
2015
Antifibrotic Therapies in the Liver
Mehal W, Schuppan D. Antifibrotic Therapies in the Liver. Seminars In Liver Disease 2015, 35: 184-198. PMID: 25974903, PMCID: PMC5743222, DOI: 10.1055/s-0035-1550055.Peer-Reviewed Original ResearchConceptsAntifibrotic therapyIdeal patient populationRegression of fibrosisBest noninvasive methodFibrolytic propertiesDose titrationClinical outcomesFibrosis regressionPulmonary fibrosisPatient populationCombination therapyLiver fibrosisIndividualized therapyEncouraging dataFibrotic responseTherapeutic targetDrug AdministrationFibrosisTherapyNoninvasive methodInterindividual heterogeneityCell populationsAntifibroticsLiverFibrolysis
2007
The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis
Mehal W, Friedman S. The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. 2007, 111-121. DOI: 10.1007/978-1-59745-518-3_10.Peer-Reviewed Original ResearchHepatic fibrosisChronic liver diseaseRole of inflammationWound healing responseViral hepatitisLiver diseaseFibrosis progressionAutoimmune diseasesChronic injuryLiver fibrosisCellular sourceFibrosisExtracellular matrixDiseaseRealistic expectationsUbiquitous responseMajor advancesTranscriptional eventsHepatitisInflammationPatientsPathophysiologyPathogenesisInjuryLiver